We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News Medica 2024 AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

DePuy AcroMed to Buy Link Spine Group for $325 Million

By HospiMedica staff writers
Posted on 19 May 2003
In a move that will give the company exclusive worldwide rights to a widely used artificial disc, DePuy AcroMed (Raynham, MA, USA) has agreed to acquire Link Spine Group (Branford, CT, USA) for a US$325 million upfront payment and further payments contingent upon achievement of regulatory and other milestones. DePuy Acromed is a Johnson & Johnson company.

The principal product of Link Spine Group is the SB Charite artificial disc, approved and marketed in more than 30 countries worldwide. The disc is designated by the US Food and Drug Administration (FDA) with an Investigational Device Exemption in clinical studies.

"The SB Charite artificial disc represents an important advancement in the treatment of spinal disorders,” said Ncholas Valeriani, group chairman with management responsibility for the DePuy franchise. "For many patients, total disc arthroplasty should provide a significant medical benefit. This investment underscores DePuy's commitment to innovative technology and advancing the standard of care for patients around the world.”





Related Links:
DePuy Acromed
Link Spine Group

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Diagnosis Display System
C1216W
New
Transcatheter Heart Valve
SAPIEN 3 Ultra

Latest Business News

Boston Scientific Acquires Medical Device Company Intera Oncology

MEDICA 2024 to Highlight Hot Topics of MedTech Industry

Start-Ups To Once Again Play Starring Role at MEDICA 2024